drugset / Trial / NCT05271279
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multi-center, open-label, single-arm, investigator-initiated clinical trial to evaluate the safety and efficacy of oncolytic virus injection (OVV-01) in combination with trained immunity NK (tiNK) cell injection (IBR900) for patients with advanced malignant tumors.
Timeline
- Start
- 2021-12-24
- Primary completion
- 2022-08-29
- Completion
- 2022-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBR900 | Cell therapy | 4e+09 cells | — |
| Subject | OVV-01 | Unknown | — | — |